Abstract
Background: Bleomycin induced pulmonary toxicity is clinically detected using diffusing lung capacity for carbon monoxide (DLCO) in Hodgkin9s Lymphoma (HL) patients after chemotherapy. Objective: To evaluate changes in DLCO in HL patients after ABVD chemotherapy. Methods: Medical records of all adult HL patients treated with ABVD chemotherapy at a single center in Lahore, Pakistan during the entire calendar year 2012 were analyzed. Patients with pre-existing pulmonary dysfunction, history of thoracic surgery and smokers were excluded. Results: Out of 179 patients, 93 (51.95%) patients had received both a pre- and post-chemotherapy DLCO. The mean percentage difference between pre- and post-chemotherapy values for DLCO (5.49%; 95% confidence interval [CI] 1.56%-9.43%) and for Hemoglobin-adjusted DLCO (8.24%; 95% CI 3.90%-12.57%) were statistically significant at p 2 increase in dose of Bleomycin was significantly associated with 0.14% (95% CI: 0.03%-0.25%) decline in DLCO and 0.13% (95% CI: 0.10%-0.26%) decline in hemoglobin-adjusted DLCO from pretreatment value. Conclusions: Mild to moderate dysfunction in diffusion lung capacity is common after ABVD chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
